Harbour BioMed names Bob Zhang president of metabolic disease franchise

PUBT · 2d ago
Harbour BioMed names Bob Zhang president of metabolic disease franchise
  • HBM Holdings appointed Dr. Bob Zhang president of its metabolic disease franchise on Aug. 6, 2026; he will be based in Shanghai.
  • Zhang will report to founder, chairman, CEO Dr. Jingsong Wang; remit includes franchise strategy, R&D, partnerships, NewCo incubation.
  • Move signals a push into obesity, MASH, metabolic liver disease, cardiovascular disorders; focus on next-generation antibody biologics.
  • Zhang previously led Epigenic Therapeutics as co-founder, CEO; served as CEO of Kunming Biomed International, translational medicine director at Sanofi.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN20737) on August 06, 2026, and is solely responsible for the information contained therein.